Friday 6 November 2026
Export HRMY’s income statement to Excel — free account
Harmony Biosciences Holdings, Inc.
HRMY Healthcare Biotechnology
Harmony Biosciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $868.5 million, up 21.5% from fiscal 2024.
- Revenue
- +12.3%
- EPS
- −6.24%
- Free cash flow
- −29.4%
- Total debt
- −11.5%
Quarter to September 2026, against a year earlier
33.04
0.57
+1.76%
Follow HRMY
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
5 | 4 | 4 | 4 |
| 20.75% | 17.86% | 20.46% | 18.73% | ||
| 13.98% | 12.51% | 14.61% | 13.30% | ||
ROIC |
50.40% | 27.66% | 29.70% | 30.45% | |
Return on Tangible Assets |
24.23% | 25.93% | 31.24% | 26.93% | |
Average Days of Receivables |
40.68 | 43.93 | 42.21 | 47.13 | |
Free Cash Flow per Share |
6.05 | 5.91 | 6.13 | 5.53 | |
Free Cash Flow |
347.89 | 341.97 | 355.08 | 323.04 | |
Capital Expenditures |
(0.31) | — | — | — | |
| Other line items | |||||
Cash ROIC |
19.23% | 20.00% | 19.50% | 16.21% | |
Accounts Receivable Turnover |
9.66 | 8.40 | 9.41 | 8.66 | |
Accounts Payable Turnover |
12.62 | 9.16 | 9.44 | 9.65 | |
Inventory Turnover |
31.60 | 36.15 | 37.87 | 40.30 | |
Average Days of Payables |
32.56 | 49.51 | 33.55 | 38.24 | |
Days of Inventory on Hand |
9.86 | 9.14 | 9.84 | 8.34 | |
Tax Rate |
(0.26) | (0.26) | (0.25) | (0.23) | |
Research and Development Expense of Revenue |
21.83% | 24.96% | 23.01% | 24.01% | |
Selling, General and Administrative Expense of Revenue |
31.33% | 30.51% | 28.39% | 27.84% | |
Share Based Compensation of Revenue |
5.17% | 4.78% | 4.26% | 3.84% | |
Interest Coverage |
14.23 | 13.49 | 17.12 | 16.99 | |
Operating CF/Net income |
2.19 | 2.35 | 1.96 | 1.81 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
(0.01) | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
15.11 | 15.55 | 16.57 | 16.94 | |
Operating CF per Share |
6.06 | 5.91 | 6.13 | 5.53 | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 6 Nov 2026